Is AbbVie the Best Dividend King to Buy in September?

AbbVie has a fantastic dividend track record. The company's rock-solid business should help maintain its dividend growth streak for a long time.

The Motley Fool • 12 hours ago

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • 12 hours ago

How AbbVie's Neuroscience Portfolio Has Transformed Over the Years

ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.

Zacks Investment Research • 9 hours ago

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline

AbbVie NYSE: ABBV executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company's established SKYRIZI and RINVOQ franchises.

MarketBeat • Sep 15, 2026

AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 15, 2026

Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit

R&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics. A featured SkinMedica ® R&D panel on exosomes will introduce the FACTS Principles and examine the scientific questions shaping responsible innovation in this rapidly evolving category.

PRNewsWire • Sep 15, 2026

AbbVie (ABBV) Advances While Market Declines: Some Information for Investors

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.

Zacks Investment Research • Sep 14, 2026

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates billions in annual free cash flow and continues to expand its market share in immunology treatments. CRISPR Therapeutics is a leader in gene editing with a groundbreaking partnership to commercialize transformative medicines.

The Motley Fool • Sep 14, 2026

Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

AbbVie is a diversified pharmaceutical company. Its dividend yields 2.7% -- and that payout has been growing.

The Motley Fool • Sep 12, 2026

What's Going On With AbbVie Stock Friday?

AbbVie Inc. (NYSE:ABBV) shares are edging higher Friday morning following Thursday's announcement of positive Phase 3 trial results for its menstrual migraine treatment, atogepant. Here's what investors need to know.

Benzinga • Sep 11, 2026